Compare FF & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FF | AKBA |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.3M | 251.0M |
| IPO Year | 2005 | 2014 |
| Metric | FF | AKBA |
|---|---|---|
| Price | $4.62 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 284.2K | ★ 5.6M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.32% | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.09 | $0.82 |
| 52 Week High | $5.12 | $4.04 |
| Indicator | FF | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 69.23 |
| Support Level | $3.87 | $1.32 |
| Resistance Level | $4.69 | $1.56 |
| Average True Range (ATR) | 0.21 | 0.09 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 73.99 | 87.21 |
FutureFuel Corp makes and sells diversified chemical products, bio-based fuel products, and specialty chemical products. The company is organized into two segments based on product type: biofuels and chemicals. The biofuels segment sells biodiesel and other petroleum products, with fuels made from a mix of diesel, vegetable oils, and grease feedstock. The chemicals segment, which generates the majority of revenue, sells products used in the production of agricultural chemicals, including herbicides, as well as coatings and cleaning products such as detergents.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.